CAS No.: | 2381089-83-2 |
---|---|
Formula: | C50h69n15o9 |
EINECS: | 1308068-626-2 |
Type: | Pharmaceutical Intermediates |
Appearance: | Powder |
Quality: | Technical |
Samples: |
---|
Customization: |
---|
Suppliers with verified business licenses
Cagrilintide alone, as well as cagrilintide in combination with semaglutide have shown promising weight loss in clinical trials that supports the further development of this therapy for sustained weight management.
What Is Retatrutide?
Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity.Cagrilintide is under development for the treatment of obesity and type 2 diabetes. The drug candidate is administered as a once-daily and once weekly subcutaneous formulation. It is a long-acting amylin analogue. Amylin is co-located with isulin in secretory granules and co-secreted with isulin by pancreatic beta cells in response to food intake.
Cagrilintide is an amylin-analog, now being developed in combination with the GLP-1 agonist semaglutide to achieve sustained weight loss in persons with overweight and obesity. Amylin, released with isulin from beta cells in the pancreas, induces its satiating effect via both the homoeostatic and hedonic regions of the brain.
You Get What You Paid For :
2mg | 5mg | 10mg | |
Semaglutide | $70/Box | $120/Box | $210/Box |
Tirzepatide | $85/Box | $130/Box | $240/Box |
Retatrutide | $125/Box | $220/Box | $370/Box |
It's in US Dollar, 10vials per Box. Price is negotiated if order in bulk. Good quality with after-sale
service superior to peers.
Purchasing objects are required to be companies and labs, not for personal use.
Semaglutide belongs to a class of medications known as glucagon-like peptide-1 receptor agonists,
or GLP-1 RAs. It mimics the GLP-1 hormone, released in the gut in response to eating. One role of GLP-1 is to
prompt the body to produce more isulin, which reduces blood sugar (glucose).
Tirzepatide FDA Approves New Medication for Chronic Weight Management.Tirzepatide (Mounjaro) is used for weight loss and type 2 diabetes in adults. Tirzepatide is a GIP and GLP-1 receptor agonist and works for weight loss by
decreasing your appetite and slowing the movement of food from the stomach into the small intestine, which may make
you feel full more quickly and for a longer period of time. Tirzepatide also decreases blood sugar levels by increasing
isulin production and lowering the amount of sugar the liver makes.
Retatrutide (LY-3437943) is under development for the treatment of type 2 diabetes mellitus, obstructive sleep
apnea, osteoarthritis, obesity and non-alcoholic fatty liver disease. The drug candidate is administered through
subcutaneous and intravenous route. The drug candidate acts by targeting glucagon-like peptide 1 (GLP-1),
glucose-dependent isulinotropic polypeptide (GIP), and glucagon receptors. It is a new molecular entity.
All Peptides For Research Purpose Only, abuse is prohibited.
Suppliers with verified business licenses